Literature DB >> 26700144

New surprises from an old favourite: The emergence of telomerase as a key player in the regulation of cancer stemness.

Kerem Teralı1, Açelya Yilmazer2.   

Abstract

It has been well established that the upregulation/reactivation of telomerase is a prerequisite for cellular immortalisation and malignant transformation. More significantly, perhaps, telomerase stands at the crossroads of multiple signalling pathways and its upregulation/reactivation leads to the modulation of critical cellular processes, including gene expression and metabolism. In recent years, this multifaceted ribonucleoprotein particle has become increasingly associated with the cancer stem cell (CSC) phenotype in various human cancers. Cancer stemness is a major contributor to therapy resistance and hence tumour recurrence. Here, we discuss new findings about the telomere-independent tumour-promoting functions of telomerase and provide a mechanistic explanation for its regulatory role in CSC biology. It is striking that there is a positive feedback loop between a number of gene products targeting telomerase's reverse transcriptase subunit (TERT) and TERT expression itself. This plausibly amplifies the effects of central oncogenes and oncogenic pathways related to cancer stemness in a cell-autonomous fashion. A more complete elucidation of these regulatory mechanisms affords the opportunity to develop telomerase-focused therapies that differentiate or kill CSCs effectively.
Copyright © 2015 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  CSCs; Cancer stemness; Positive feedback loops; TERT; Targeted anticancer therapy; Telomerase

Mesh:

Substances:

Year:  2015        PMID: 26700144     DOI: 10.1016/j.biochi.2015.12.001

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

1.  A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Authors:  Ralph Salloum; Trent R Hummel; Shiva Senthil Kumar; Kathleen Dorris; Shaoyu Li; Tong Lin; Vinay M Daryani; Clinton F Stewart; Lili Miles; Tina Young Poussaint; Charles Stevenson; Stewart Goldman; Girish Dhall; Roger Packer; Paul Fisher; Ian F Pollack; Maryam Fouladi; James Boyett; Rachid Drissi
Journal:  J Neurooncol       Date:  2016-06-27       Impact factor: 4.130

Review 2.  Telomerase and drug resistance in cancer.

Authors:  Natalia Lipinska; Aleksandra Romaniuk; Anna Paszel-Jaworska; Ewa Toton; Przemyslaw Kopczynski; Blazej Rubis
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

3.  Azidothymidine inhibits cell growth and telomerase activity and induces DNA damage in human esophageal cancer.

Authors:  Haoli Wang; Jianwen Zhou; Qiong He; Yu Dong; Yanhui Liu
Journal:  Mol Med Rep       Date:  2017-05-03       Impact factor: 2.952

Review 4.  Implications of telomeres and telomerase in endometrial pathology.

Authors:  D K Hapangama; A Kamal; G Saretzki
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

5.  Azidothymidine "Clicked" into 1,2,3-Triazoles: First Report on Carbonic Anhydrase-Telomerase Dual-Hybrid Inhibitors.

Authors:  Emanuela Berrino; Andrea Angeli; Dmitry D Zhdanov; Anna P Kiryukhina; Andrea Milaneschi; Alessandro De Luca; Murat Bozdag; Simone Carradori; Silvia Selleri; Gianluca Bartolucci; Thomas S Peat; Marta Ferraroni; Claudiu T Supuran; Fabrizio Carta
Journal:  J Med Chem       Date:  2020-06-10       Impact factor: 7.446

Review 6.  Therapeutic Targeting of Telomerase.

Authors:  Kathrin Jäger; Michael Walter
Journal:  Genes (Basel)       Date:  2016-07-21       Impact factor: 4.096

7.  Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy.

Authors:  Sara Benedetti; Narumi Uno; Hidetoshi Hoshiya; Martina Ragazzi; Giulia Ferrari; Yasuhiro Kazuki; Louise Anne Moyle; Rossana Tonlorenzi; Angelo Lombardo; Soraya Chaouch; Vincent Mouly; Marc Moore; Linda Popplewell; Kanako Kazuki; Motonobu Katoh; Luigi Naldini; George Dickson; Graziella Messina; Mitsuo Oshimura; Giulio Cossu; Francesco Saverio Tedesco
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.